Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Pulmonary Embolism Therapeutics market. The report identifies the key trends shaping and driving the global Pulmonary Embolism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Pulmonary Embolism Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Pulmonary Embolism Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Pulmonary Embolism Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Pulmonary Embolism Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Pulmonary Embolism Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Pulmonary Embolism Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Pulmonary Embolism Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Pulmonary Embolism Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Pulmonary Embolism Therapeutics market landscape? – Identify, understand and capitalize.

Table Of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Pulmonary Embolism (PE) - Introduction 7
2.1 Overview 7
2.2 Epidemiology 7
2.3 Etiology 7
2.3.1 Stagnant Blood Flow 7
2.3.2 Coagulation 7
2.3.3 Damage to the Vein Walls 7
2.3.4 Other Risk Factors 7
2.4 Clinical Presentation/Symptoms 8
2.5 Diagnosis 8
2.5.1 Electrocardiography 8
2.5.2 Chest Radiography 8
2.5.3 Arterial Blood Gas (ABG) Determination 8
2.5.4 Computed Tomographic Pulmonary Angiography 8
2.5.5 Ventilation-Perfusion Scanning 8
2.5.6 Magnetic Resonance Angiography 8
2.5.7 Biomarkers (Troponins and Brain Natriuretic Peptide) 8
2.5.8 Echocardiography (Transthoracic and Transesophageal) 9
2.6 Pathophysiology 9
2.7 Treatment 10
2.7.1 Anticoagulation 10
2.7.2 Unfractionated Heparin (UFH) 10
2.7.3 Low Molecular Weight Heparin (LMWH) 10
2.7.4 Indirect Factor Xa Inhibitors 10
2.7.5 Thrombolytic agents 10
2.7.6 Warfarin 10
2.8 Other Procedures and Devices for Pulmonary Embolism 11
2.8.1 Pulmonary Embolectomy 11
2.8.2 Vena Caval Interruption 11
2.9 GlobalData Pipeline Report Guidance 11
3 Pulmonary Embolism Therapeutics - Market Characterization 12
3.1 Overview 12
3.2 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Global 12
3.3 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Global 14
3.4 Pulmonary Embolism Therapeutics Market Size (2006-2011) - The US 15
3.5 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - The US 16
3.6 Pulmonary Embolism Therapeutics Market Size (2006-2011) - France 17
3.7 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - France 18
3.8 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Germany 19
3.9 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Germany 20
3.10 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Italy 21
3.11 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Italy 22
3.12 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Spain 23
3.13 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Spain 24
3.14 Pulmonary Embolism Therapeutics Market Size (2006-2011) - The UK 25
3.15 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - The UK 26
3.16 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Japan 27
3.17 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Japan 28
3.18 Drivers and Barriers for the Pulmonary Embolism Therapeutics Market 29
3.18.1 Drivers for the Pulmonary Embolism Therapeutics Market 29
3.18.2 Barriers for the Pulmonary Embolism Therapeutics Market 29
3.19 Opportunity and Unmet Need 30
3.20 Key Takeaway 31
4 Pulmonary Embolism Therapeutics Market - Competitive Assessment 32
4.1 Overview 32
4.2 Strategic Competitor Assessment 32
4.3 Product Profiles of the Major Marketed Products in the Pulmonary Embolism Therapeutics Market - Heparin Class 33
4.3.1 Enoxaparin (Lovenox or Clexane) 33
4.3.2 Dalteparin (Fragmin) 34
4.3.3 Warfarin 36
4.3.4 Xarelto 36
4.3.5 Fondaparinux (Arixtra) 38
4.3.6 Apixaban (Eliquis) 39
4.4 Key Takeaway 41
5 Pulmonary Embolism Therapeutics Market - Pipeline Assessment 42
5.1 Overview 42
5.1.1 Pulmonary Embolism Therapeutics -Phase III Clinical Pipeline 42
5.1.2 Pulmonary Embolism Therapeutics - Phase II Clinical Pipeline 43
5.1.3 Pulmonary Embolism Therapeutics - Regulatory and Phase I Clinical Pipeline 43
5.1.4 Pulmonary Embolism Therapeutics - Preclinical and Discovery Clinical Pipeline 43
5.2 Pulmonary Embolism Therapeutics Market - Pipeline Assessment by Mechanism of Action 44
5.3 Pulmonary Embolism Therapeutics Market - Technology Trends Analytical Framework 45
5.4 Pulmonary Embolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 47
5.5 Pulmonary Embolism Therapeutics - Promising Drugs under Clinical Development 47
5.6 Molecule Profile for Promising Drugs under Clinical Development 48
5.6.1 Edoxaban 48
5.7 Key Takeaway 48
6 Pulmonary Embolism Therapeutics - Clinical Trials Mapping 49
6.1 Clinical Trials by Region/Country 49
6.2 Clinical Trials by Phase of Clinical Development 50
6.3 Clinical Trials by Trial Status 51
6.4 Prominent and Overall Sponsors 52
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials 54
7 Pulmonary Embolism Therapeutics - Strategic Assessment 55
7.1 Key Events Impacting the Future Market 55
7.2 Future Market Competition Scenario 56
8 Pulmonary Embolism Therapeutics - Future Players 57
8.1 Introduction 57
8.1.1 Boehringer Ingelheim GmbH 57
8.1.2 Bristol-Myers Squibb 58
8.1.3 Daiichi Sankyo 59
8.1.4 Pfizer Inc. 61
8.1.5 Sanofi 62
9 Pulmonary Embolism Therapeutics Market - Appendix 64
9.1 Market Definition 64
9.2 Abbreviations 64
9.3 Methodology 65
9.3.1 Coverage 65
9.3.2 Secondary Research 66
9.3.3 Forecasting 66
9.3.4 Primary Research 68
9.3.5 Expert Panel Validation 69
9.4 Contact Us 69
9.5 Disclaimer 69
9.6 Bibliography 69

List of Tables

Table 1: Pulmonary Embolism Therapeutics Market, Global, Revenues ($m), 2006-2011 13
Table 2: Pulmonary Embolism Therapeutics Market, Global, Market Forecasts ($m), 2011-2019 14
Table 3: Pulmonary Embolism Therapeutics Market, The US, Revenue ($m), 2006-2011 15
Table 4: Pulmonary Embolism Therapeutics Market, The US, Market Forecasts ($m), 2011-2019 16
Table 5: Pulmonary Embolism Therapeutics Market, France, Revenue ($m), 2006-2011 17
Table 6: Pulmonary Embolism Therapeutics Market, France, Market Forecast ($m), 2011-2019 18
Table 7: Pulmonary Embolism Therapeutics Market, Germany, Revenue ($m), 2006-2011 19
Table 8: Pulmonary Embolism Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 20
Table 9: Pulmonary Embolism Therapeutics Market, Italy, Revenue ($m), 2006-2011 21
Table 10: Pulmonary Embolism Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 22
Table 11: Pulmonary Embolism Therapeutics Market, Spain, Revenue ($m), 2006-2011 23
Table 12: Pulmonary Embolism Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 24
Table 13: Pulmonary Embolism Therapeutics Market, The UK, Revenue ($m), 2006-2011 25
Table 14: Pulmonary Embolism Therapeutics Market, The UK, Market Forecast ($m), 2011-2019 26
Table 15: Pulmonary Embolism Market, Japan, Revenue ($m), 2006-2011 27
Table 16: Pulmonary Embolism Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 28
Table 17: Major Marketed Products Comparison in the Pulmonary Embolism Therapeutics Market, 2011 40
Table 18: Pulmonary Embolism Therapeutics Market - Phase III Clinical Pipeline, 2011 42
Table 19: Pulmonary Embolism Therapeutics Market - Phase II Clinical Pipeline, 2011 43
Table 20: Pulmonary Embolism Therapeutics Market - Phase I Clinical Pipeline, 2011 43
Table 21: Pulmonary Embolism Therapeutics Market - Preclinical Pipeline, 2011 43
Table 22: Pulmonary Embolism Therapeutics - Most Promising Drugs under Clinical Development, 2011 47
Table 23: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials, 2011 49
Table 24: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Phase, 2011 50
Table 25: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Status of Development, 2011 51
Table 26: Pulmonary Embolism Therapeutics Market, Global, Sponsors, 2011 53
Table 27: Pulmonary Embolism Therapeutics Market, Global, Companies by Phase, 2011 54

List of Figures

Figure 1: Pulmonary Embolism Clinical Presentation 9
Figure 2: Pulmonary Embolism Therapeutics Market, Global, Revenues ($m), 2006-2011 13
Figure 3: Pulmonary Embolism Therapeutics Market, Global, Market Forecast ($m), 2011-2019 14
Figure 4: Pulmonary Embolism Therapeutics Market, The US, Revenue ($m), 2006-2011 15
Figure 5: Pulmonary Embolism Therapeutics Market, The US, Market Forecasts ($m), 2011-2019 16
Figure 6: Pulmonary Embolism Therapeutics Market, France, Revenue ($m), 2006-2011 17
Figure 7: Pulmonary Embolism Therapeutics Market, France, Market Forecast ($m), 2011-2019 18
Figure 8: Pulmonary Embolism Therapeutics Market, Germany, Revenue ($m), 2006-2011 19
Figure 9: Pulmonary Embolism Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 20
Figure 10: Pulmonary Embolism Therapeutics Market, Italy, Revenue ($m), 2006-2011 21
Figure 11: Pulmonary Embolism Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 22
Figure 12: Pulmonary Embolism Therapeutics Market, Spain, Revenue ($m), 2006-2011 23
Figure 13: Pulmonary Embolism Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 24
Figure 14: Pulmonary Embolism Therapeutics Market, The UK, Revenue ($m), 2006-2011 25
Figure 15: Pulmonary Embolism Therapeutics Market, The UK, Market Forecast ($m), 2011-2019 26
Figure 16: Pulmonary Embolism Therapeutics Market, Japan, Revenue ($m), 2006-2011 27
Figure 17: Pulmonary Embolism Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 28
Figure 18: Opportunity and Unmet Need in the PE Therapeutics Market 30
Figure 19: Strategic Competitor Assessment of the Marketed Products for Pulmonary Embolism, 2011 33
Figure 20: Pulmonary Embolism Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 44
Figure 21: Technology Trends Analytic Framework of the Pulmonary Embolism Pipeline, 2011 45
Figure 22:Technology Trends Analytic Framework of the Pulmonary Embolism Pipeline - Description, 2011 46
Figure 23: Pulmonary Embolism Pipeline by Phase of Clinical Development, 2011 47
Figure 24: Pulmonary Embolism Market, Global, Clinical Trials by Country, 2011 49
Figure 25: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Phase, 2011 50
Figure 26: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Stage of Development, 2011 51
Figure 27: Pulmonary Embolism Therapeutics Market, Global, Prominent Sponsors, 2011 52
Figure 28: Pulmonary Embolism Therapeutics Market, Global, Overall Sponsors, 2011 52
Figure 29: Pulmonary Embolism Therapeutics Market, Global, Companies by Phase, 2011 54
Figure 30: Pulmonary Embolism Therapeutics Market, Drivers and Restraints, 2011 55
Figure 31: Implications for Future Market Competition in the Pulmonary Embolism Therapeutics Market, 2011 56
Figure 32: Pulmonary Embolism Therapeutics Market - Clinical Pipeline by Company, 2011 57
Figure 33: GlobalData Market Forecasting Model 68

Companies mentioned
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
Daiichi Sankyo
Pfizer Inc.
Sanofi

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • April 2014
  • by Global Markets Direct

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Corcept Therapeutics Incorporated - Product Pipeline Review - 2014', provides an overview of the Corcept ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.